TACT2 CLINICAL TRIAL

Chelation for Patients who have Diabetes and had a Heart Attack

 

Chelation Therapy

Chelation Therapy is an intravenous treatment to remove heavy metals and to improve circulation.  It has been in use for over 50 years with many anecdotal reports of significant improvement in cardiovascular status, circulation, neuropathy, and quality of life. Until the chelation clinical trial called TACT I was published in 2013, however, no rigorous clinical trial had clearly demonstrated efficacy.  This all changed with the publication of these results in JAMA in 2013.  This was a landmark study, with thousands of patients, hundreds of medical institutions involved, and over 55,000 IV’s administered.  The general consensus among traditional medicine physicians prior to publication of the results was that the trial was a waste of time and would show no benefit.  Much to their surprise, not only did the TACT trial show that chelation was helpful, it was dramatic, especially among diabetics.  The other positive was that it was shown to be extremely safe, with 55,000 IV’s administered and side effects reported as “minimal.”

TACT 2 is a follow up study to TACT I.  It is a clinical trial to determine whether intravenous (IV) disodium EDTA chelation therapy with oral multivitamins will reduce the risk of major cardiovascular events (such as heart attacks and strokes) in diabetic patients who have had a heart attack.

The chelation therapy used in the TACT 2 study consists of 40 IV treatments (administered through a vein in your arm) of disodium ethylene diamine tetra-acetic acid also known as disodium EDTA, vitamins, and other dissolved materials. Disodium EDTA is thought to bind toxic metals in the body, including lead and cadmium, that may contribute to the development of heart disease.

What does this trial involve?

This trial is designed to determine how heavy metals in the body may be causing many dangerous health problems (such as heart attacks and strokes) and how chelation therapy may be able to reduce the levels of these metals in the body thus reducing the risk for these dangerous health problems.

You may qualify if:

  • You are over the Age of 50
  • Are Diabetic
  • Have a History of a Heart Attack
  • Can Commute to Landrum, SC

Benefits of this Research Study:

  • Free Study Medication
  • Free Study Related Care
  • Compensation for Travel for Those Who Qualify

Leave a Reply

Your email address will not be published.